arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Protagonist Therapeutics, Inc

PTGX
$145.99 ▼ -0.33 (-0.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
46 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protagonist Therapeutics, Inc faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $9.5B
Dividend Yield
Revenue Growth 99.0%
Op. Margin -6.5%
ROIC -0.9%
FCF / Share $-0.76
Trailing P/E 2433.2x
Price / Book 14.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

46-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$56.37M
↑ +99.0%
Net Income Profit after all expenses
$3.78M
↑ +108.5%
Operating Margin Operating profit as % of sales
-6.5%
↑ +90.5% 0th
FCF / Share Free cash flow per share
$-0.76
↓ -2278.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
34
Returns
27
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 46 quarters